Tilray: Cantor Slashes Price Target To $7.40 Ahead Of Earnings

Tilray (TSX: TLRY) is expected to report its second fiscal quarter 2022 results on January 10 before the markets open. The average revenue estimate between 14 analysts is US$172.62 million. This average estimate has steadily been revised lower as the estimate is down from US$211.18 million at the start of July 2021.

Tilray currently has 20 analysts covering the stock with an average 12-month price target of US$10.60, or a 65% upside to the current stock price. Out of the 20 analysts, 1 has a strong buy rating, 2 have buys, 14 have hold ratings and the last 3 analysts have sell ratings on Tilray. The street high sits at US$23 while the lowest 12-month price target comes in at US$0.82.

Cantor Fitzgerald cut their 12-month price target on Tilray from $11.80 to $7.40 while reiterating their neutral rating on the stock. This comes ahead of the companies second fiscal quarter results as they expect the company’s stock to “face pressure from the Nov quarter print,” unless management comes out with bullish commentary during the earnings call.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

The biggest drivers Cantor believes will move the stock this quarter are Hyfire data showing Tilray quarter sales dropping 16% sequentially as the market grew 5%, and cannabis gross margins continue to fall. This is primarily due to operating deleverage and continued pricing wars.

For the quarterly results, Cantor expects Tilray to report $164 million and adjusted EBITDA of $10 million, as compared to the street’s estimate of $174 million and $14 million, respectively. The main reason for the difference is due to recent Hyfire data, showing that both Tilray and legacy Aphria products are down 16% this quarter compared to last, with December market share trends not pointing to any improvement. They say that although Tilray remains the company with the largest market share at 10.8%, it has lost 8% year over year.

Lastly, Cantor brings up the issue regarding Aphria Diamond, as Tilray only holds 51% of the company. Aphria Diamond has a capacity of 255 tons and Cantor values Tilray’s portion at $200 million. As of the August quarter, there was a minority interest loss of $41.6 million, but a profit of $14.4 million. This means that “Tilray shareholders do not own the full earnings at Aphria Diamond.” Cantor says that if you deduct the minority interest, Tilray is trading at 12x cannabis sales while Canopy is trading at 12x.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Goliath Extends Golden Gate Lode 130 Metres With 13.45 g/t Gold Equivalent Over 4.85 Metres

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Related News

NG Energy: Beacon Raises Price Target To $3 Following Resource Update

On March 18th, NG Energy (TSXV: GASX) released an updated estimate for their natural gas...

Monday, March 22, 2021, 11:51:00 AM

Valens: Canaccord Lowers Price Target To $3.75

Earlier this month, The Valens Company (TSX: VLNS) reported their fiscal third-quarter financial results. The...

Sunday, October 31, 2021, 10:10:00 AM

Valens: Second Quarter Consensus Estimates

The Valens Company (TSX: VLNS) announced that they will be reporting their second quarter financials...

Tuesday, July 13, 2021, 02:30:00 PM

Tilray Brands Posts Net Loss Of $85 Million In Q2 2025

Tilray Brands (TSX: TLRY) this morning reported its second quarter financial results, posting topline revenue...

Friday, January 10, 2025, 09:07:34 AM

Canaccord Drops Medmen Price Target To $0.00, Reiterates Sell Rating

After Medmen Enterprises’ (CSE: MMEN) fourth-quarter results dropped after hours on October 15th, Canaccord downgraded...

Friday, October 16, 2020, 12:22:53 PM